Search clinical trials for: SHR-A2009; SHR-1316

Total 1770 results

Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Atridia Pty Ltd.

Active, not recruiting

Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Korea, Republic of, China, Japan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors

Tumor
Atridia Pty Ltd.

Completed

A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients

Advanced Solid Tumors

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Advanced Malignant Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors

Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

Pharmacokinetic
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Australia, China
Atridia Pty Ltd.

Completed

A Study of SHR-1314 in Healthy Subjects

Psoriasis

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients

Active Moderate to Severe Graves' Orbitopathy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Moderate-to-Severe Plaque Psoriasis

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

Bioequivalence
Tongji Hospital

Recruiting

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

Breast Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer

Limited-stage Small Cell Lung Cancer, LS-SCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis

Psoriatic Arthritis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Beijing Suncadia Pharmaceuticals Co., Ltd

Not yet recruiting

Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects

Diabetes
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis

Lupus Nephritis
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis

Moderate-to-Severe Plaque Psoriasis
Atridia Pty Ltd.

Completed

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Solid Tumors and Hematologic Malignancy

Australia
Sanjay Gandhi Postgraduate Institute of Medical...
Ram Manohar Lohia Institute of Medical Sciences, Lucknow

Terminated

Re-treatment of HCV Following DAA Failure

Chronic Hepatitis C

India
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Plaque Psoriasis

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Safety, Tolerability and PK of SHR1314 in axSpA

Axial Spondyloarthritis

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Esophageal Squamous Cell Carcinoma | Progression to PD-1 Antibody

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.

Alzheimer's Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Asthma With Eosinophilic Phenotype

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Primary Hypercholesterolemia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

Non-Small-Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Qian Chu
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (CAPSTONE)

Sarcomatoid Carcinoma of Lung

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Alzheimer's Disease

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

Prevention of Graft Rejection After Organ Transplantation

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

T2DM

China
Henan Cancer Hospital

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Eosinophilic Granulomatosis With Polyangiitis

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Beijing Suncadia Pharmaceuticals Co., Ltd

Active, not recruiting

Safety and Tolerability of SHR-1918 in Healthy Subjects

Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Advanced Solid Tumors

China
Shanghai Pulmonary Hospital, Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

China

3

Subscribe